ARTICLE | Company News
Arakis, KS Biomedix arthritis deal
March 7, 2001 8:00 AM UTC
Arakis ( Cambridge, U.K.) and KS Biomedix (LSE:KSB) will co-develop compounds for arthritis. The deal involves two preclinical compounds: Arakis' AD 452 single isomer cytokine modulator and KSB's KSB3...